Transaction Details

Footnotes

On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. | The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.